Cellular Biomedicine Group Announces Positive 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin® Therapy
January 13, 2016 08:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis ReJoin® Stem Cell Therapy
December 22, 2015 09:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...